What is type 2 acute coronary syndrome (ACS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Type 2 Acute Coronary Syndrome?

Type 2 ACS (also called Type 2 myocardial infarction) is myocardial necrosis caused by an imbalance between myocardial oxygen supply and demand that is NOT due to acute coronary plaque rupture, erosion, or thrombosis. 1

Key Distinguishing Features from Type 1 MI

Type 2 MI fundamentally differs from Type 1 MI in its underlying mechanism 1:

  • Type 1 MI: Caused by acute coronary atherothrombosis from plaque rupture, ulceration, fissure, erosion, or dissection with resulting intraluminal thrombus 1
  • Type 2 MI: Caused by supply-demand mismatch unrelated to acute coronary plaque instability 1

Mechanisms and Precipitating Causes

Type 2 MI results from various conditions that create oxygen supply-demand imbalance 1:

Supply-side problems:

  • Coronary artery spasm 1
  • Coronary endothelial dysfunction 1
  • Severe hypotension 1
  • Respiratory failure/hypoxia 1
  • Severe anemia 1

Demand-side problems:

  • Tachyarrhythmias 1
  • Bradyarrhythmias 1
  • Severe hypertension 1
  • Hypertrophic cardiomyopathy 1
  • Severe aortic stenosis 1

Other mechanisms:

  • Sepsis (most common precipitant, particularly from lower respiratory tract) 1, 2
  • Pharmacological agents and toxins in critically ill patients 1
  • Major non-cardiac surgery 1
  • Pulmonary embolism 1
  • Severe heart failure 1

Diagnostic Criteria

Type 2 MI requires the same diagnostic criteria as any acute MI 1:

  • Elevated cardiac troponin (preferably high-sensitivity) with rise and/or fall pattern, with at least one value above the 99th percentile upper reference limit 1

PLUS at least one of:

  • Symptoms of ischemia 1
  • New or presumed new significant ST-T wave changes or left bundle branch block 1
  • Development of pathological Q waves 1
  • Imaging evidence of new loss of viable myocardium or regional wall motion abnormality 1

Critical caveat: The diagnosis requires appropriate clinical context—elevated troponin alone is insufficient and must be interpreted with the clinical picture to distinguish Type 2 MI from Type 1 MI or non-ischemic myocardial injury 1

Clinical Recognition Challenges

Type 2 MI is significantly underdiagnosed in clinical practice 3:

  • In one study of 224 patients meeting objective criteria for Type 2 MI, clinicians diagnosed it in only 3 (1.3%) cases, despite 80.4% receiving cardiology consultations 3
  • The heterogeneity of precipitating causes and lack of consensus on diagnostic criteria contribute to poor recognition 3
  • Distinguishing Type 2 from Type 1 MI retrospectively can be extremely difficult, as both may present with similar troponin elevations and ECG changes 1

Patient Characteristics and Risk Factors

Patients with Type 2 MI typically have 2:

  • High prevalence of comorbidities: Diabetes mellitus (74.57%), hypertension (69.49%), and dyslipidemia (64.4%) 2
  • Mean age: Approximately 70 years 2
  • Multiple simultaneous comorbidities: Most patients have more than two risk factors 2

Management Approach

The primary management strategy is treating the underlying precipitating cause 1, 3:

  1. Identify and correct the supply-demand imbalance: Address sepsis, anemia, arrhythmias, hypotension, respiratory failure, or other precipitants 1, 2

  2. Coronary evaluation is still warranted: Despite the Type 2 classification, many patients have underlying significant coronary artery disease 3:

    • In patients without pre-existing heart disease who had Type 2 MI, 64.2% had significant coronary lesions when explored 3
    • Patients with Type 2 MI and no pre-existing heart disease should be prioritized for coronary exploration 3

  3. Risk stratification factors influencing exploration decisions 3:

    • Age (younger patients more likely to be explored) 3
    • Family history of coronary disease 3
    • ECG presentation 3
    • Left ventricular ejection fraction 3
    • Cardiology consultation 3

Clinical Outcomes

Type 2 MI carries significant morbidity and mortality 2:

  • Mortality rate: 32.20% in one prospective study 2
  • Heart failure: Develops in 57.62% of patients 2
  • Arrhythmias: Occur in 22.03% of patients 2
  • Poorer outcomes: Documented worse outcomes compared to other MI types, particularly in South Asian populations 2

Important Clinical Pitfalls

Do not assume Type 2 MI excludes significant coronary disease: The high rate of underlying coronary lesions (64.2%) in Type 2 MI patients without known heart disease means coronary evaluation should not be deferred based solely on the Type 2 classification 3

Do not rely on troponin elevation alone: Type 2 MI diagnosis requires clinical context—sepsis, renal failure, myocarditis, and other conditions can elevate troponin without ischemia 1

Recognize the diagnostic challenge: The distinction between distal embolization from non-occlusive thrombus (Type 1) and supply-demand mismatch from atherosclerosis (Type 2) may be impossible to determine retrospectively 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the recommended primary‑prevention treatment strategy according to Canadian guidelines for a 40‑year‑old male with total cholesterol 5.8 mmol/L, LDL 4.24 mmol/L, HDL 0.91 mmol/L, lipoprotein(a) 224 mg/dL, a strong family history of premature coronary artery disease (father with MI in his 50s and triple bypass in his 70s), who is not diabetic, not on any medication, does not smoke tobacco but uses one cannabis joint daily?
What is the recommended medication regimen for acute coronary syndrome?
Is an ALT level of 39 U/L normal, and what management is recommended?
Can testosterone therapy affect lipoprotein(a) levels?
Should sertraline (Zoloft) 50 mg be changed in a 35‑year‑old woman who has been stable on it for a year but reports somnolence, has vitamin D deficiency, low folate, normal liver enzymes, and borderline high LDL and total cholesterol?
Can a reactive hepatitis B surface antigen (HBsAg) result occur after hepatitis B vaccination without acute infection?
Do mechanics and truck drivers have an increased risk of shoulder strain compared with the general population?
In a patient started on furosemide (Lasix) 40 mg twice daily for congestion, when should the medication be discontinued and the study repeated?
How long should prasugrel be held before a colonoscopy?
Why is hemoglobin A1c (HbA1c) unreliable in a liver transplant recipient receiving tacrolimus?
Is intravenous iron sucrose (Monoferric) safe to administer before magnetic resonance imaging (MRI)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question